Ardelyx, Inc. (ARDX)
$
4.03
+0.12 (2.98%)
Key metrics
Financial statements
Free cash flow per share
-0.2042
Market cap
971.4 Million
Price to sales ratio
2.6855
Debt to equity
1.0647
Current ratio
4.1230
Income quality
0.8843
Average inventory
22.5 Million
ROE
-0.3445
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines aimed at treating various gastrointestinal and cardiorenal conditions both in the United States and internationally. The company's lead product candidate, tenapanor, has successfully completed Phase III clinical trials for treating patients suffering from irritable bowel syndrome with constipation and is also undergoing Phase III trials to manage serum phosphorus levels in adult patients with chronic kidney disease (CKD) undergoing dialysis, a condition known as hyperphosphatemia. Ardelyx is additionally developing RDX013, a potassium secretagogue designed to address elevated serum potassium levels, or hyperkalemia, which is particularly relevant for certain patients with kidney or heart disorders. Furthermore, RDX020 is being investigated as an early-stage program targeting metabolic acidosis, a serious electrolyte imbalance affecting patients with CKD. The company has established collaborations with Kyowa Kirin for development in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. for China, and Knight Therapeutics, Inc. in Canada for commercializing tenapanor in those regions. The company's financial metrics show that the EBITDA is -$16,713,000.00 a key indicator of the company's operational profitability, while the gross profit stands at $283,059,000.00 highlighting its earnings from core operations. The weighted average number of diluted shares outstanding is 235,232,927.00 which reflects potential dilution effects, and the company reported depreciation and amortization expenses of $2,063,000.00 illustrating the wear and tear of its assets. Ardelyx’s stock is identified with the symbol 'ARDX' in the market. Investors may find the stock appealing, as it is affordable at $4.03 making it suitable for budget-conscious individuals. The stock boasts a high average trading volume of 5,240,324.00 indicating strong liquidity and interest from the market. With a market capitalization of $964,197,650.00 Ardelyx is classified as a small-cap player, which often indicates growth potential. It is recognized as a key player in the Biotechnology industry, contributing significantly to the overall market landscape and driving innovation and growth in the Healthcare sector. This positioning enhances its ability to attract attention from both investors and collaborators in the field of biopharmaceuticals.
Is Ardelyx, Inc. (ARDX) a good investment?
Investing in Ardelyx, Inc. (ARDX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as D+, with a Bullish outlook. Always conduct your own research before investing.
What is Ardelyx, Inc. (ARDX)'s stock forecast?
Analysts predict Ardelyx, Inc. stock to fluctuate between $3.21 (low) and $8.06 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Ardelyx, Inc.'s market capitalization?
As of 2025-05-29, Ardelyx, Inc.'s market cap is $964,197,650, based on 239,255,000 outstanding shares.
How does Ardelyx, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Ardelyx, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Ardelyx, Inc. (ARDX) stock?
To buy Ardelyx, Inc. (ARDX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ARDX. Place an order (Market, Limit, etc.).
What is the best time to invest in Ardelyx, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Ardelyx, Inc. stock ever split?
Ardelyx, Inc.'s last stock split was 4:1 on 2021-07-20.
How did Ardelyx, Inc. perform in the last earnings report?
Revenue: $333,615,000 | EPS: -$0.17 | Growth: -43.33%.
Where can I find Ardelyx, Inc.'s investor relations reports?
Visit https://www.ardelyx.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Ardelyx, Inc.?
You can explore historical data from here
What is the all-time high and low for Ardelyx, Inc. stock?
All-time high: $10.13 (2024-02-12) | All-time low: $0.49 (2022-06-16).
What are the key trends affecting Ardelyx, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
accessnewswire.com
NEW YORK CITY, NY / ACCESS Newswire / May 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ:ARDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
accessnewswire.com
NEW YORK CITY, NY / ACCESS Newswire / May 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ:ARDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
accessnewswire.com
NEW YORK CITY, NY / ACCESS Newswire / May 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ:ARDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
globenewswire.com
NEW YORK, May 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Ardelyx, Inc. ("Ardelyx, Inc.") (NASDAQ:ARDX) concerning possible violations of federal securities laws. Ardelyx issued a press release on May 1, 2025, reporting its financial results for the first quarter of 2025.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Ardelyx, Inc. ("Ardelyx, Inc.") (NASDAQ:ARDX) concerning possible violations of federal securities laws. Ardelyx issued a press release on May 1, 2025, reporting its financial results for the first quarter of 2025.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Ardelyx, Inc. ("Ardelyx, Inc.") (NASDAQ:ARDX) concerning possible violations of federal securities laws. Ardelyx issued a press release on May 1, 2025, reporting its financial results for the first quarter of 2025.
prnewswire.com
NEW YORK , May 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Ardelyx, Inc. ("Ardelyx, Inc.") (NASDAQ:ARDX) concerning possible violations of federal securities laws. Ardelyx issued a press release on May 1, 2025, reporting its financial results for the first quarter of 2025.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Ardelyx, Inc. ("Ardelyx, Inc.") (NASDAQ:ARDX) concerning possible violations of federal securities laws. Ardelyx issued a press release on May 1, 2025, reporting its financial results for the first quarter of 2025.
See all news
